Caution, this is an AI generated summary based on literature. This may have errors, see here for more.
Please share your feedback with us.
MIR128-2: MIR128-2 is a miRNA that has been found to be recurrently aberrant in expression in various studies [PMC3566410]. Mutant TP53 has been shown to bind to the putative promoter of the MIR128-2 host gene ARPP21, leading to increased expression of both miR-128 and ARPP21 mRNA [PMC4302087]. A mutation in the MIR128-2 gene, specifically the A13G mutation, has been found to reduce the processing of pri-miR-128-2 and result in glucocorticoid resistance in t(4;11) ALL cells [PMC9406077]. Additionally, mutp53 R175H has been shown to induce the expression of MIR128-2, which targets E2F5 and confers resistance to various cancer treatments [PMC7749743]. MIR128-1 and MIR128-2 are members of the miRNA MIR128 family and encode the same mature miR-128, which plays different roles in tumorigenesis depending on cancer type [PMC7802300]. A three-miRNA signature called miGISig, which includes MIR421, MIR128-1, and MIR128-2, has been identified as predictive of gastrointestinal (GI) cancer and clinical outcome [PMC7802300]. Dysregulation of both MIR128-1 and MIR128-2 has also been observed in glioblastomas [PMC3821381]. The genes encoding miR-128 transcripts are located on different chromosomes (MIR128 family on chromosome 3p22; ARPP21 gene on chromosome 3p22) but encode identical mature sequences with slight differences in their 5p species [PMC5481840].
Genome locations
Gene Ontology annotations
Ancestor Chart
Loading ontology ancestors...
Failed to load QuickGO Ancestor chart
Sequence
Sequence features are shown above as colored rectangles.
Zoom in and click to view details, or
Reset